###### Strengths and limitations of this study

-   Although systematic reviews of acupuncture for stable angina pectoris have been conducted previously, this study will update the evidence base by including many clinical trials that have been published in the past 5 years.

-   Rating the efficacy--effectiveness spectrum of trials included in the systematic review has the potential to indicate how close current evidence is to 'real-world' practice.

-   As several clinical outcomes have been used in published trials, a pooled analysis of all included studies may not be possible; however, subgroup analyses will be performed according to different outcomes.

Background {#s1}
==========

Stable angina pectoris (SAP) is a prevalent cardiovascular disease that greatly compromises a patient's life quality and longevity. It is a clinical syndrome involving temporary hypoxic myocardial ischaemia and features sensations of burning, severe pain, pressure and other forms of discomfort in the left anterior chest region. In the USA, SAP affects more than 7.8 million people and is reported to have an incidence of more than 0.5 million cases per year.[@R1] In the European population, its incidence is estimated to be 10%--20% of people aged 65--74 years.[@R2] Within China, the prevalence is 2.4% among men and 3.2% among women,[@R3] which makes it a serious public health problem. According to the 2013 European Society of Cardiology guidelines on the management of stable coronary artery disease,[@R4] current treatment options for SAP are diverse, generally including lifestyle modification and elimination of risk factors, pharmacological management and revascularisation.

Although many therapeutic interventions are available to patients, the management of SAP is not satisfactory. Most patients continue to suffer from SAP or the side effects of their medications.[@R5] Non-pharmacological therapies as secondary options are frequently chosen by patients. Acupuncture, a major component of traditional Chinese medicine, has been extensively used by clinicians for the management of acute attacks and for prophylaxis of SAP since ancient times.[@R6] The clinical practice of acupuncture involves a series of procedures that entail the insertion of filiform needles into designated acupuncture points, followed by different needle manipulation techniques. Clinical observations and expert opinions suggest that acupuncture has the potential to reduce disease duration, angina attack frequency and nitroglycerin consumption, and improve cardiac work capacity.[@R8] Studies suggest that acupuncture may exert a myocardial protection and vascular dilation effect against cardiac ischaemia and reperfusion by inhibiting the beta (1)-adrenoceptor signalling pathway and regulating myocardial enzyme action.[@R12] Therefore, acupuncture has the potential to be an effective supplementary treatment option for SAP.

However, the effect of acupuncture for SAP is still controversial from the perspective of evidence-based medicine. Several systematic reviews have been conducted to assess the clinical benefits of acupuncture therapy for SAP, but all of them, including the most recent, which reviewed studies before 2013, were inconclusive due to poor-quality trials.[@R18] Recently, it has been noticed with great interest that a rough estimation of at least 10 clinical studies has been published or conducted in the past 5 years.[@R6] These studies have great potential to change the current evidence base of acupuncture for SAP. However, at present there exists no updated systematic review or study protocol published on this question. We thus have a unique opportunity to re-evaluate the issue and conceive this systematic review to determine the effectiveness and safety of acupuncture for patients with SAP based on the most comprehensive and up-to-date resources.

Methods {#s2}
=======

Criteria for including studies in the review {#s2a}
--------------------------------------------

### Types of studies {#s2a1}

The review will include randomised controlled trials (RCT) that were reported in any language. Completed and ongoing trials will be included. Trials using a two-arm or three-arm parallel design will be included. Crossover trials and quasi-RCTs will be excluded. Any study with a sample size of less than 10 participants will also be excluded from this review.

### Types of participants {#s2a2}

Trials including participants who meet the diagnostic criteria of SAP or stable coronary heart disease will be included.[@R30] All eligible study participants will be included in this review regardless of their age, race or gender. Trials including study participants who are not appropriate to receive acupuncture therapy, such as pregnant or lactating women and those with additional severe diseases, will be excluded.

### Types of interventions {#s2a3}

The interventions considered in the studies must involve needle insertion at acupuncture points, pain points or trigger points, and be described as acupuncture. Adjunct therapy with acupuncture that is additive to the active treatment will be included in this review. However, other methods of stimulating acupuncture points without needle insertion (such as moxibustion, laser stimulation, massage or transcutaneous electrical nerve stimulation) will be excluded. Studies that compare the efficacy of different forms of acupuncture will be excluded as this is not the focus of the review.

### Types of comparator(s)/control {#s2a4}

The following control groups will be considered:Acupuncture versus sham devices (interventions mimicking 'verum' acupuncture/treatment, but deviating in at least one aspect considered important by acupuncture theory, such as skin penetration or non-acupoint location).Acupuncture versus routine care.Acupuncture versus conventional drugs.Acupuncture in addition to active treatment versus active treatment alone.

Studies that only compare different forms of acupuncture or compare acupuncture with other complementary and alternative therapeutic interventions shall be excluded.

### Types of outcome measures {#s2a5}

#### Primary outcomes {#s2a5a}

The number of weekly angina attacks and nitroglycerin use during a period of at least 2 weeks following randomisation.

#### Secondary outcomes {#s2a5b}

1.  Cardiovascular events.

2.  ECG changes (mainly ST-segment depression).

3.  Heart rate variability.

4.  Angina pain intensity (assessed by visual analogue scale).

5.  Affective emotions (assessed by self-rating anxiety scale and self-rating depression scale).

6.  Total workload (in Met-minutes) and exercise duration (in seconds) at peak exercise.

7.  Overall tolerability.[@R34]

8.  Overall acceptability.[@R34]

Search methods for identification of studies {#s2b}
--------------------------------------------

### Electronic searches {#s2b1}

The following databases will be searched from their inception to September 2017: MEDLINE, Ovid, EMBASE, Cochrane Library, the Allied and Complementary Medicine Database (AMED), Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang Database, the Chongqing VIP Chinese Science and Technology Periodical Database (VIP). Only RCTs that evaluate the effect of acupuncture in comparison with the aforementioned comparator controls will be included. There will be no language restriction on the included trials. The following medical search headings (MeSH) will be used: stable angina pectoris, stable angina, angina pectoris, angina, acupuncture, acupuncture therapy, electroacupuncture, electroacupuncture therapy, manual acupuncture, acupoint, randomised controlled trial, randomised controlled, randomised, controlled, clinical trial, comparative study, prospective study. Chinese translations of these search terms will be used for the Chinese databases. The searching strategy for MEDLINE is listed in [table 1](#T1){ref-type="table"}. The search strategy will be modified according to the Cochrane Handbook for Systematic Reviews[@R35] for other databases.

###### 

Search strategy in MEDLINE

  ------ ------------------------------------------------------
  \#1    randomized controlled trial \[pt\]
  \#2    controlled clinical trial \[pt\]
  \#3    randomized \[tiab\]
  \#4    placebo \[tiab\]
  \#5    clinical trials as topic \[mesh: noexp\]
  \#6    randomly \[tiab\]
  \#7    trial \[ti\]
  \#8    \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6 OR \#7
  \#9    animals \[mh\] NOT humans \[mh\]
  \#10   \#8 NOT \#9
  \#11   angina, stable \[mesh\]
  \#12   chronic stable angina pectoris \[tiab\]
  \#13   stable angina pectoris \[tiab\]
  \#14   chronic stable angina \[tiab\]
  \#15   stable angina \[tiab\]
  \#16   angina pectoris \[ti\]
  \#17   angina \[ti\]
  \#18   \#11 OR \#12 OR \#13 OR \#14 OR \#15 OR \#16 OR \#17
  \#19   acupuncture \[mesh\]
  \#20   acupuncture therapy \[mesh\]
  \#21   electroacupuncture \[tiab\]
  \#22   electroacupuncture therapy \[tiab\]
  \#23   manual acupuncture \[tiab\]
  \#24   dry needle \[tiab\]
  \#25   acupoint \[tiab\]
  \#26   \#19 OR \#20 OR \#21 OR \#22 OR \#23 OR \#24 OR \#25
  \#27   \#10 AND \#18 AND \#26
  \#28   remove duplicates from \#27
  ------ ------------------------------------------------------

### Searching other resources {#s2b2}

Ongoing trials with unpublished data will be retrieved from the following clinical trial registries: the NIH clinical registry ClinicalTrials.gov (<https://www.clinicaltrials.gov/>), the International Clinical Trials Registry Platform (ICTRP) (<http://www.who.int/ictrp/en/>), the Australian New Zealand Clinical Trials Registry (<http://www.anzctr.org.au/>) and the Chinese clinical registry (<http://www.chictr.org/en/>). The list of all identified publications including relevant systematic reviews and meta-analyses will be reviewed to further identify additional trials. Useful but incomplete data will be obtained for data synthesis from the contact trial personnel.

Data collection and analysis {#s2c}
----------------------------

### Selection of studies {#s2c1}

The search results will be imported from the original databases to Endnote V.X7.1. Two reviewers (MY and MS) will independently assess the eligibility of the retrieved studies according to the inclusion criteria. For preliminary study selection, only the title and abstract will be reviewed to exclude obviously inappropriate publications. Unmatched studies will be removed to a trash box in the software. The reasons for exclusion will be recorded as an Excel data set. The next step will be to further evaluate the included studies by reading their full-text version. The reference list will be checked by the two reviewers to identify potentially missing trials. The selection results will be cross-checked by the two reviewers. Any disagreement will be resolved by consensus. Further argument will be arbitrated by a third reviewer (TD). Each eligible trial will be assigned a study ID formatted as follows: surname of the first author + space + year of publication (eg, Yang 2017).

### Data extraction and management {#s2c2}

Two reviewers (HL and ZS) will independently double-check the eligibility of the included studies and extract data by entering details into a predefined data acquisition form. This acquisition form will include four main domains: citation information (title, author list, source of publication, year of publication, first author's name and affiliation, country, sponsor), design (design, participants, trial methods, duration, intervention details, caregiver information), results (outcome measures, adverse events) and conclusion. Any discrepancy noticed in the process of data cross-checking will be resolved through discussion and the suggestion of a third reviewer (LL).

### Assessment of risk of bias in included studies {#s2c3}

The risk of bias for each included trial will be evaluated using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials.[@R36] Two reviewers (MY and TD) will input the relevant details of each trial into the RevMan software[@R37] (V.5.3) and assess the trial for at least six domains (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias if necessary). For each domain, the trial will be rated as high, unclear or low risk of bias. A trial that is rated high risk of bias in one or more domains will be rated as 'high risk', while a low risk of bias in all domains will be rated as 'low risk'. If there is low or unclear risk of bias for all key domains, the trial will be rated as 'unclear risk'.[@R36] The contact person or corresponding author will be contacted if basic information is missing for the risk of bias assessment. The rating results will be cross-checked and discrepancies resolved through discussions and the arbitration of a third reviewer (FL).

### Measures of treatment effect {#s2c4}

Efficacy data will be synthesised and statistically analysed in RevMan V.5.3. Dichotomous data will be analysed by using a risk ratio with 95% CIs. For continuous outcomes, data will be analysed by using a weighted mean difference (WMD) or a standard mean difference (SMD) with 95% CIs. The WMD will be used for the same scale or same assessment instrument; SMD will be used for different assessment tools.

### Unit of analysis issues {#s2c5}

The units of each outcome from different trials will be converted to the International System of Units before statistical analysis.

### Dealing with missing data {#s2c6}

Whether the data were missing on purpose or 'at random' will be predetermined by contacting the corresponding author or relevant author. Available data will be analysed following confirmation by investigators that the data were missing 'at random'.[@R35] If not, a request for missing data will be sent to the original investigators of the trial, or the contact person recorded in the trial registry. In case of no reply from the authors or contact person, we will impute the missing data with replacement values, treating these as if they were observed. The last observation carried forward imputation method will be used to assume a missing value and then an intention-to-treat analysis will be performed. Moreover, if possible, we will perform sensitivity analyses to assess how sensitive the results are to reasonable changes in the assumptions that are made. The potential impact of the effect of missing data on the final findings of the review will be addressed in the discussion.

### Assessment of heterogeneity {#s2c7}

Χ^2^ tests will be performed in the forest plot using RevMan V.5.3 to investigate the statistical heterogeneity and a p value of less than 0.10 will be considered significant, in line with the Cochrane Handbook.[@R35] Moreover, the I^2^ value will be calculated to quantify the impact of the statistical heterogeneity on the meta-analysis. The Cochrane Handbook classifies the I^2^ values into four categories: 0%--40%, might not be important; 30%--60%, indicates moderate heterogeneity; 50%--90%, represents substantial heterogeneity; 75%--100%, suggests considerable heterogeneity.

### Assessment of reporting biases {#s2c8}

A funnel plot will be generated to observe the reporting bias when more than 10 trials are included.[@R35]

### Data synthesis {#s2c9}

Clinical data will be imported into RevMan software (V.5.3) to perform data synthesis. Data will be synthesised and analysed depending on the level of statistical heterogeneity. If the heterogeneity tests show little or no statistical heterogeneity in these trials, the fixed effects model will be used for the pooled data. If significant heterogeneity is detected (if the I^2^ value is no less than 50%), the random effects model will be used for data synthesis. If there is considerable heterogeneity in the trials, meta-analysis will not be performed. In this case, we will try to identify the source of heterogeneity from both clinical and methodological aspects and a narrative, qualitative summary will be provided.

### Subgroup analysis and investigation of heterogeneity {#s2c10}

If data are available, a subgroup analysis will be conducted according to variations in the characteristics of the trial participants and acupuncture treatments. When considerable heterogeneity is detected in a previous analysis, a subgroup analysis will be performed if necessary.

### Sensitivity analysis {#s2c11}

Sensitivity analysis will be used to monitor the robustness of the primary decision made in the review process. We will consider several decision nodes within the process of the systematic review to implement a sensitivity review, such as small studies, methodological weaknesses and missing data. The sensitivity analysis will involve two steps, as suggested by the Cochrane Handbook: first, including all studies as the primary meta-analysis does and second, including those that are definitely known to be eligible. The results of the sensitivity analysis will be presented in summary tables. The risk of bias in the review process, as indicated by the results of the sensitivity analysis, will be discussed.

### Other analysis {#s2c12}

Consideration will be given to using a metaregression analysis to investigate the impact of the year of publication on the outcome estimates.

### Evidence quality evaluation {#s2c13}

The reviewers will use the online Grading of Recommendations Assessment, Development and Evaluation (GRADE) application, GRADEpro (<https://gradepro.org/>), to independently assess the quality of evidence for each outcome.[@R38] Evidence quality will be rated 'high', 'moderate', 'low' or 'very low' according to the GRADE rating standards.[@R39] The quality of evidence of a specific study will be assessed according to the appropriateness of the study design, soundness of implementation, directness and precision of evidence, consistency or homogeneity of the results and other biases. A summary of findings table will be generated and included in the final report.

### Efficacy--effectiveness spectrum analysis {#s2c14}

Because systematic reviews can include both explanatory trials and pragmatic trials for data synthesis, it is important for clinicians and researchers to know the nature of the evidence. Therefore, to analyse the efficacy--effectiveness spectrum of each included trial, the Rating of Included Trials on the Efficacy-effectiveness Spectrum scale[@R41] will be used. Four domains will be assessed to justify the efficacy--effectiveness spectrum for each trial: participant characteristics, trial setting, flexibility of interventions and clinical relevance of interventions.

Ethics and dissemination {#s2d}
------------------------

This review will not involve private information from individuals or compromise their rights, and therefore does not require ethical approval. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. Due to the paucity of related publications in the field, this review article will, by adding more recent studies into the analysis, provide more robust evidence of acupuncture therapy for treating stable angina, and lead to informed clinical practice and acupuncture research.
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